Written and maintained by CASRAI Editorial Board
Last updated
Short answer
A biological assay (or bioassay) is an analytical method that measures the concentration, potency, or biological activity of a substance by observing its specific effect on living cells, tissues, or intact organisms. Unlike purely chemical tests, bioassays evaluate functional pharmacological activity relative to a characterized reference standard.
Definition and scope
In life science laboratories and biopharmaceutical manufacturing, an assay in biology is a standardized procedure designed to evaluate the presence, quantity, or functional activity of a target entity. When the assay employs living biological systems to measure functional response, it is termed a biological assay or bioassay.
Under United States regulations in 21 CFR 610.10, tests for potency for licensed biological products must consist of in vitro or in vivo tests, or both, designed to demonstrate the specific ability of a product to effect a given result as defined in 21 CFR 600.3(s). Physical and chemical methods—such as chromatography or mass spectrometry—characterize molecular mass and purity, but cannot confirm whether a complex molecule retains the higher-order structure required to trigger physiological responses. Biological assays directly quantify this functional activity.
The scope of biological assays spans drug discovery, vaccine release, environmental toxicology, and bioprocess control. Bioassays are essential for therapeutic macromolecules, including monoclonal antibodies, recombinant proteins, gene therapy vectors, and cellular therapies, where clinical efficacy depends on a verified mechanism of action.
How it works or how it is used in practice
Biological assays do not provide absolute physical mass measurements. Instead, they operate as comparative systems governed by pharmacopeial frameworks such as United States Pharmacopeia chapters: USP 1032 (Design and Development of Biological Assays), USP 1033 (Biological Assay Validation), and USP 1034 (Analysis of Biological Assays).
Reference standards and relative potency
Because living test systems exhibit biological variability across days and cell passages, an absolute response measurement cannot reliably indicate product strength. Bioassays resolve this by testing an unknown sample concurrently against a calibrated reference standard under identical conditions. Potency is calculated as a relative potency ratio (test preparation relative to reference preparation), ensuring comparability across independent runs.
Dose-response modeling
Bioassays evaluate multiple concentrations across a dilution series to generate a dose-response profile. In biological systems, the relationship between concentration and response typically follows a sigmoidal curve. As described in USP 1032, data are modeled using four-parameter logistic (4PL) or five-parameter logistic (5PL) regression models. For practical curve-fitting procedures, refer to our guide on four-parameter logistic (4PL) ELISA standard curve fitting.
Parallelism testing
A fundamental requirement for determining relative potency is demonstrating parallelism between the reference standard and test sample curves. Under USP 1032 and USP 1034, parallelism confirms that the test sample acts as a simple dilution of the reference standard, sharing equivalent upper and lower asymptotes and identical hill slopes. If non-parallelism occurs, relative potency varies across concentrations, invalidating the assay result.
Assay validation parameters
Before implementation in regulated quality control, bioassays undergo formal validation following USP 1033. Evaluated parameters include relative accuracy, intermediate precision across analysts and runs, specificity, and linearity of relative potency. Reliable testing also depends on verified instrumentation, as discussed in our guide on equipment qualification vs. validation vs. calibration.
Types or related concepts
Biological assays are categorized by biological complexity and detection mechanism. Sourced from the NIH NCATS Assay Guidance Manual and USP 1032, the primary bioassay formats include:
| Assay Format | Biological System | Readout Modality | Variability and Throughput | Primary Laboratory Application |
|---|---|---|---|---|
| In Vivo Bioassay | Intact animal models (e.g., mice, guinea pigs) | Physiological response, survival, antibody titer | High biological variability; low throughput | Vaccine challenge tests, pyrogenicity testing, complex toxicological assessment |
| Cell-Based Functional Assay | Engineered or primary cell cultures | Reporter luminescence, cell proliferation, cytokine release | Moderate variability; medium-to-high throughput | Lot-release potency testing for monoclonal antibodies and cell therapies |
| Biochemical / Enzymatic Assay | Purified enzymes, substrates, or cofactors | Spectrophotometric absorbance, fluorescence polarization | Low variability; high-throughput screening (HTS) | Enzyme inhibition kinetics, kinase activity screens in drug discovery |
| Ligand-Binding / Immunoassay | Immobilized antibodies, receptors, or antigens | Colorimetric ELISA, surface plasmon resonance (SPR) | Low variability; high throughput | Target binding affinity, quantification via direct ELISA assay formats |
Where it matters for labs, clinics or supply decisions
Biological assays serve as critical decision gates in laboratory research and biomanufacturing:
- Lot Release and Regulatory Compliance: Under 21 CFR 610.10, commercial distribution of biologics requires lot release testing with validated potency assays to ensure every distributed batch meets clinical specifications.
- Product Stability and Expiration Dating: Biologics degrade, aggregate, or denature during storage. Physical tests may miss subtle structural shifts; bioassays verify functional potency throughout the product shelf life.
- Reagent and Consumable Control: Cell-based assays are sensitive to raw materials. Variations in cell culture media, microplate surfaces, or serum lots—such as batches of fetal bovine serum—introduce baseline drift. Laboratories implement qualification programs for critical consumables to ensure consistent performance.
- Cell Line Maintenance and Authentication: Cross-contamination or genetic drift in host cell lines undermines assay reproducibility. Maintaining strict passage limits and routine verification via cell line authentication preserve assay fidelity.
Common misunderstandings
Key misconceptions in bioassay development and interpretation include:
- Equating chemical quantity with biological potency: Two samples containing identical physical masses of protein can display different potencies if one has experienced denaturation or aggregation.
- Treating parallelism as optional: In relative potency assays, parallelism is the mathematical foundation. Without parallel curves, relative potency cannot be expressed as a valid constant value.
- Assuming binding demonstrates functional efficacy: Ligand-binding assays measure physical affinity, but binding does not guarantee downstream intracellular signaling. Regulators often require cell-based functional assays to verify biological response.
- Neglecting microplate edge effects: In 96-well and 384-well plates, thermal and evaporative gradients between perimeter and interior wells introduce spatial bias, as highlighted in the NIH NCATS Assay Guidance Manual.
Frequently asked questions
What is meant by biological assay?
A biological assay is an analytical procedure that measures the concentration, potency, or activity of a substance by assessing its functional effect on a living biological system compared to a calibrated reference standard.
What are examples of biological assays?
Common examples include cell proliferation assays to quantify growth factors, reporter gene assays measuring receptor signaling, antibody-dependent cellular cytotoxicity (ADCC) assays for therapeutic antibodies, and in vitro virus neutralization assays.
What is an assay in biology?
In biology, an assay is any experimental procedure used to qualitatively detect or quantitatively measure the presence, amount, or functional activity of a target biological molecule, organism, or biochemical process.
What are types of bioassay?
Bioassays are broadly categorized into in vivo animal bioassays, in vitro cell-based functional assays, cell-free biochemical assays, and quantal or qualitative bioassays evaluating all-or-none biological endpoints.
Sources
- U.S. Food and Drug Administration. 21 CFR 610.10: Tests for potency. Code of Federal Regulations, Title 21. URL: https://www.ecfr.gov/current/title-21/chapter-I/subchapter-F/part-610/subpart-B/section-610.10
- U.S. Food and Drug Administration. Guidance for Industry: Potency Tests for Cellular and Gene Therapy Products. FDA Center for Biologics Evaluation and Research (CBER), 2011. URL: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/potency-tests-cellular-and-gene-therapy-products
- United States Pharmacopeial Convention. General Chapter 1032: Design and Development of Biological Assays. USP-NF. URL: https://www.usp.org
- United States Pharmacopeial Convention. General Chapter 1033: Biological Assay Validation. USP-NF. URL: https://www.usp.org
- National Center for Advancing Translational Sciences (NCATS), National Institutes of Health. Assay Guidance Manual. Markossian S, et al., editors. NCBI Bookshelf ID: NBK53196. URL: https://www.ncbi.nlm.nih.gov/books/NBK53196/
- National Center for Advancing Translational Sciences (NCATS). Toolkit for Patient-Focused Therapy Development: Bioassays. National Institutes of Health. URL: https://toolkit.ncats.nih.gov/module/discovery/bioassays/
